In the middle of March, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Potassium Sulphate API from NMPA.

Potassium sulfate is a colorless crystal with low hygroscopicity and has a wide application in the field of medicine. It can be used to prepare laxative, diuretic and other drugs, is the starting raw material of variety potassium salts such as potassium carbonate, potassium persulfate.

It also plays an important role in the treatment of soluble barium salt poisoning, which is conducive to regulating the content of potassium ions in the body, treating hypokalemia and preventing urinary calculi. 

In addition, potassium sulfate can also be used as an additive to drugs to improve the stability and effect of drugs, such as for the biochemical test of serum protein, Kjeldahl catalyst for nitrogen determination, determination of blood potassium and other potassium salts. According to statistics, magnesium sodium potassium sulfate oral concentrated solution began to be sold in China in 2022, and achieved rapid growth in global sales in a short time.

This authorization indicate that Jiudian market will make further progress.